New York – February 2, 2024 – Cooley advised Graviton Bioscience, a privately held clinical-stage biotechnology company focused on therapies that inhibit Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) and other therapeutic compounds, on its strategic investment from Sanofi. Partners Brandon Fenn and Alan Tamarelli led the Cooley team advising Graviton Bioscience.
Under the terms of the agreement, Sanofi receives a right of first negotiation to license compounds across various indications – including immunological and metabolic syndrome indications – driving the momentum behind ROCK2 inhibitor treatments.